More efficient, smaller multicancer screening trials

Intended-effect or targeted analysis may substantially reduce the sample size needed to evaluate cancer-specific mortality in blood-based screening trials. Targeted analysis requires many fewer retrospective tests and avoids potential problems arising from the need to inform those individuals whose stored samples test positive. Trialists should consider the trade-off of costs between sample size and retrospective testing requirements when choosing the analysis method.